{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:02:54Z","timestamp":1794708174468,"version":"4.9.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This update begins with a section on inflammatory myopathies covering inclusion body myositis in younger patients, the possibility of a pathogenic role for anti-cN1A antibodies, and a negative trial of arimoclomol in inclusion body myositis. The potential study of Janus kinase inhibitors in dermatomyositis is discussed as well as the possible role of targeted therapy for immune checkpoint inhibitor neuromuscular complications. Next, studies of disease-modifying or potential disease-modifying therapies for inherited myopathies are addressed including the encouraging follow-up study of gene replacement therapy for Duchenne muscular dystrophy (DMD), a negative trial of tamoxifen in DMD, and the complex topic of gene therapy for X-linked myotubular myopathy. A newly identified condition of muscular dystrophy from 3-hydroxy-3-methylglutaryl-CoA reductase mutations is addressed along with possible therapy. Other papers regarding <jats:italic toggle=\"yes\">GNE<\/jats:italic> myopathy and long-term outcome of enzyme replacement therapy in infantile onset Pompe disease round out that section. Updates on the expanding spectra of anoctamin-5 myopathies, caveolinopathies, and congenital and mylagic myopathies from <jats:italic toggle=\"yes\">CACNA1S<\/jats:italic> mutations follow as well as extensive discussion of Valosin containing protein proteinopathies, comprehensive management of Becker muscular dystrophy, and gastrointestinal complications in adult DMD.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000484","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T17:00:14Z","timestamp":1724173214000},"page":"16-31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["What is in the Myopathy Literature?"],"prefix":"10.1097","volume":"26","author":[{"given":"Michael","family":"Isfort","sequence":"first","affiliation":[{"name":"Departments of Neurology, Ohio State University Wexner Medical Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lacomis","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord."},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1007\/s00415-023-11878-w","article-title":"Inclusion body myositis with early onset: a population-based study","volume":"270","author":"Lindgren","year":"2023","journal-title":"J Neurol."},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front Immunol."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/jnnp-2023-331474","article-title":"Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis","volume":"94","author":"Yamashita","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol."},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect."},{"key":"R11-20250507","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol."},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","article-title":"Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study","volume":"22","author":"Fonseca","year":"2023","journal-title":"Lancet Neurol."},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"e200177","DOI":"10.1212\/NXI.0000000000200177","article-title":"Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomizedtrial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7 micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.28000","article-title":"Sustained clinical benefit following systemic gene replacement therapy in Duchenne muscular dystrophy","volume":"69","author":"McMillan","year":"2024","journal-title":"Muscle Nerve"},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S1474-4422(23)00285-5","article-title":"Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Henzi","year":"2023","journal-title":"Lancet Neurol."},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ajhg.2023.04.006","article-title":"Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophy","volume":"110","author":"Morales-Rosado","year":"2023","journal-title":"Am J Hum Genet."},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"e2217831120","DOI":"10.1073\/pnas.2217831120","article-title":"Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone","volume":"120","author":"Yogev","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"11377","DOI":"10.3390\/ijms222111377","article-title":"Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances","volume":"22","author":"G\u00f3mez-Oca","year":"2021","journal-title":"Int J Mol Sci."},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1474-4422(23)00416-7","article-title":"Gene therapy for X-linked myotubular myopathy: the challenges","volume":"22","author":"Voermans","year":"2023","journal-title":"Lancet Neurol."},{"key":"R24-20250507","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1093\/brain\/awad251","article-title":"MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy","volume":"146","author":"Giraud","year":"2023","journal-title":"Brain"},{"key":"R25-20250507","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1093\/brain\/awac489","article-title":"Tamoxifen improves muscle structure and function of Bin1- and Dnm2-related centronuclear myopathies","volume":"146","author":"Gineste","year":"2023","journal-title":"Brain"},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JND-230029","article-title":"Phase II\/III study of aceneuramic acid administration for GNE myopathy in Japan","volume":"10","author":"Suzuki","year":"2023","journal-title":"J Neuromuscul Dis."},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"e2109","DOI":"10.1212\/WNL.0000000000006932","article-title":"A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy","volume":"92","author":"Lochm\u00fcller","year":"2019","journal-title":"Neurology"},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/ene.15894","article-title":"Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: a French real-life observational study","volume":"30","author":"Tardieu","year":"2023","journal-title":"Eur J Neurol."},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1093\/brain\/awad088","article-title":"Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort","volume":"146","author":"de Bruyn","year":"2023","journal-title":"Brain"},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1111\/ene.15832","article-title":"Caveolinopathy: clinical, histological, and muscle imaging features and follow-up in a multicenter retrospective cohort","volume":"30","author":"Berling","year":"2023","journal-title":"Eur J Neurol."},{"key":"R31-20250507","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13311-018-00677-1","article-title":"Ryanodine receptor 1-related myopathies: diagnostic and therapeutic approaches","volume":"15","author":"Lawal","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R32-20250507","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00401-016-1656-8","article-title":"Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy","volume":"133","author":"Schartner","year":"2017","journal-title":"Acta Neuropathol."},{"key":"R33-20250507","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3390\/genes14071363","article-title":"Congenital myopathy as a phenotypic expression of CACNA1S gene mutation: case report and systematic review of the literature","volume":"14","author":"Marinella","year":"2023","journal-title":"Genes"},{"key":"R34-20250507","doi-asserted-by":"crossref","first-page":"e1779","DOI":"10.1212\/WNL.0000000000207639","article-title":"CACNA1S variant associated with a myalgic myopathy phenotype","volume":"101","author":"Periviita","year":"2023","journal-title":"Neurology"},{"key":"R35-20250507","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2443.2001.00447.x","article-title":"AAA+ superfamily ATPases: common structure- diverse function","volume":"6","author":"Ogura","year":"2001","journal-title":"Genes Cells"},{"key":"R36-20250507","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12031-011-9627-y","article-title":"The multiple faces of valosin-containing protein associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia and amyotrophic lateral sclerosis","volume":"45","author":"Nalbandian","year":"2011","journal-title":"J Mol Neurosci."},{"key":"R37-20250507","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp-2015-310362","article-title":"Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK","volume":"87","author":"Figueroa-Bonaparte","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R38-20250507","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng1332","article-title":"Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin containing protein","volume":"36","author":"Watts","year":"2004","journal-title":"Nat Genet."},{"key":"R39-20250507","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/acn3.51760","article-title":"Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy","volume":"10","author":"Roy","year":"2023","journal-title":"Ann Clin Translational Neurol."},{"key":"R40-20250507","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1007\/s00415-023-11862-4","article-title":"Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis","volume":"270","author":"Esteller","year":"2023","journal-title":"J Neurol."},{"key":"R41-20250507","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/WCO.0000000000001184","article-title":"Therapeutic developments for valosin containing protein mediated multisystem proteinopathy","volume":"36","author":"Boock","year":"2023","journal-title":"Curr Opin Neurol."},{"key":"R42-20250507","doi-asserted-by":"crossref","first-page":"46","DOI":"10.6000\/1927-3037.2014.03.02.2","article-title":"The influence on diet and exercise on the physical health of affected individuals with VCP disease","volume":"3","author":"Hamorsky","year":"2014","journal-title":"Int J Biotechnol Wellness Ind."},{"key":"R43-20250507","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1007\/s00415-023-11837-5","article-title":"Diagnosis and management of Becker muscular dystrophy: the French Guidelines","volume":"270","author":"Margot","year":"2023","journal-title":"J Neurol."},{"key":"R44-20250507","first-page":"1","article-title":"Adults living with Duchenne muscular dystrophy: old and new challenges in a cohort of 19 patients in the third to fifth decade","volume":"31","author":"Gadaleta","year":"2023","journal-title":"Eur J Neurol."},{"key":"R45-20250507","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.nmd.2023.10.004","article-title":"Life-threatening bowel complications in adults with Duchenne muscular dystrophy: a case series","volume":"33","author":"Nart","year":"2023","journal-title":"Neuromuscul Disord."},{"key":"R46-20250507","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.nmd.2023.10.008","article-title":"A systematic literature review and meta-analysis of the effectiveness of vitamin D supplementation for patients with Duchenne muscular dystrophy","volume":"33","author":"Guo","year":"2023","journal-title":"Neuromuscul Disord."},{"key":"R47-20250507","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy part 1: diagnosis, and neuromuscular, rehabilitation, endocrine and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"R48-20250507","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JND-200609","article-title":"Adult north star network (ANSN): consensus guideline for the standard of care of adults with Duchenne muscular dystrophy","volume":"8","author":"Quinlivan","year":"2021","journal-title":"J Neuromuscul Dis."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:02:14Z","timestamp":1746651734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000484","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}